Print

American College of Rheumatology: Anti-IL17 Drug Misses Endpoint in RA Trial, Stanford University Study  
11/11/2010 6:12:28 AM

ATLANTA -- An investigational biologic drug with a novel target in rheumatoid arthritis failed to meet its primary endpoint in a phase II placebo-controlled trial, researchers reported here.
//-->